Landmark trial
RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal
Kachnic LA, Winter K, Myerson RJ, et al. · RTOG
DoseLab summary
Phase 2 RTOG trial of dose-painted IMRT with 5-FU and mitomycin-C for anal cancer. It did not meet its primary endpoint, a reduction in grade 2+ acute gastrointestinal and genitourinary toxicity. Its normal-tissue dose goals are quoted by later protocols; DoseLab could not open a readable copy of the protocol document, so values credited to it are shown as the quoting protocol gives them. Citation checked against Europe PMC.
Why this is useful
The trial that established dose-painted IMRT for anal cancer; its normal-tissue goals are the basis of most anal cancer organ tables.
Reference details
- Title
- RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal
- Authors / organization
- Kachnic LA, Winter K, Myerson RJ, et al. · RTOG
- Publication / protocol
- Int J Radiat Oncol Biol Phys. 2013;86(1):27–33
- Version
- Pending verification
- Year
- 2013
- DOI
- 10.1016/j.ijrobp.2012.09.023
- Disease sites
- GI
- Topics
- Anal canal, IMRT, Dose painting, RTOG, Dose Constraints
- Fractionation context
- Dose-painted IMRT, 50.4–54 Gy (primary) over 28–30 fx by stage
- Last reviewed by DoseLab
- Pending verification